DR. REDDY'S LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,204 INR | -1.47% |
|
+3.13% | +7.01% |
| Sales 2024 * | 279B 3.34B | Sales 2025 * | 299B 3.58B | Capitalization | 1,033B 12.38B |
|---|---|---|---|---|---|
| Net income 2024 * | 54.64B 655M | Net income 2025 * | 56.74B 680M | EV / Sales 2024 * | 3.46 x |
| Net cash position 2024 * | 67.94B 814M | Net cash position 2025 * | 107B 1.28B | EV / Sales 2025 * | 3.1 x |
| P/E ratio 2024 * |
18.8
x | P/E ratio 2025 * |
18.1
x | Employees | 25,863 |
| Yield 2024 * |
0.66% | Yield 2025 * |
0.71% | Free-Float | 91.52% |
More Fundamentals
* Assessed data
More news
Latest transcript on Dr. Reddy's Laboratories Limited
More recommendations
More press releases
More news
| 1 day | -1.47% | ||
| 1 week | +3.13% | ||
| Current month | +0.75% | ||
| 1 month | +0.75% | ||
| 3 months | +6.17% | ||
| 6 months | +14.95% | ||
| Current year | +7.01% |
1 week
5 921.05
6 325.00
1 month
5 880.806 325.00
Current year
5 520.656 505.90
1 year
4 384.056 505.90
3 years
3 654.006 505.90
5 years
2 351.206 505.90
10 years
1 872.956 505.90
| Managers | Title | Age | Since |
|---|---|---|---|
Erez Israeli
CEO | Chief Executive Officer | 57 | 18-04-01 |
Parag Agarwal
DFI | Director of Finance/CFO | - | 20-11-01 |
| Chairman | 56 | 93-01-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gunupati Prasad
CHM | Chairman | 63 | 86-04-07 |
| Chairman | 56 | 93-01-17 | |
Kalpana Morparia
BRD | Director/Board Member | 74 | 07-06-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 6,204 | -1.47% | 381,304 |
| 24-04-29 | 6,297 | +0.72% | 297,106 |
| 24-04-26 | 6,252 | +0.54% | 412,618 |
| 24-04-25 | 6,219 | +4.50% | 926,985 |
| 24-04-24 | 5,951 | -0.02% | 266,987 |
Delayed Quote NSE India S.E., April 30, 2024 at 07:42 am EDT
More quotes
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows:
- sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines;
- sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services;
- other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc.
Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).
Sector
Pharmaceuticals
Calendar
2024-05-06
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
35
Last Close Price
6,205
INR
Average target price
6,005
INR
Spread / Average Target
-3.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +33.25% | 704B | |
| +28.59% | 577B | |
| -3.55% | 348B | |
| +18.16% | 327B | |
| +4.36% | 288B | |
| +14.81% | 234B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -3.69% | 147B |
- Stock Market
- Equities
- DRREDDY Stock
- DRREDDY Stock
